All Blogs

Mar 15, 2023

The amount of health and "omics-related data" produced and stored has increased exponentially during the last few decades. In clinical trials, patient data can be gathered in real-time and examined using various artificial intelligence (AI) techniques; mobile devices can also be utilized to enhance certain facets o...

Mar 14, 2023

Sanofi to Acquire Provention Bio for USD 2.9 Billion Sanofi and Provention Bio, Inc., a publicly traded biopharmaceutical company based in the United States focused on intercepting and preventing immune-mediated diseases such as type 1 diabetes (T1D), have agreed to acquire Provention Bio, Inc. for $25.00 per sh...

Mar 13, 2023

Cancer is the second leading cause of death worldwide, after ischemic heart disease. There are approximately 200 different types of cancer, with lung, prostate, colorectal, stomach, and liver cancer being the most common in men and breast, colorectal, lung, cervical, and thyroid cancer being the most common in wome...

Jul 25, 2024

Over the years, REVLIMID has become an integral weapon in the cancer therapeutics armory. This odyssey of REVLIMID in the multiple myeloma segment began in 2005, when it was approved by the US FDA for the treatment of adult patients with multiple myeloma, in combination with dexamethasone.  As the wise say,...

Mar 09, 2023

New Commercial & Residential Electric Whole-Body Cryotherapy Machines Released by Artica Systems  On March 2, 2023, Artica Systems, an American company with over 20 years of experience in the wellness industry announced the release of a new and innovative 100% electric, whole-body cryotherapy fleet mean...

Mar 08, 2023

Burn is one of the most severe and rapidly growing burdens worldwide, leading to a very high number of mortality and morbidity yearly. It can have intense physical, socioeconomic, and psychological consequences on the person and their family. As per the latest assessment by DelveInsight, incident cases of burns req...

Mar 07, 2023

Incyte Halts Phase III Clinical Trial for Myelofibrosis  Incyte announced the termination of Phase III LIMBER-304 trial after the results of a pre-planned interim analysis conducted by an independent data monitoring committee (IDMC) revealed that the study is unlikely to meet the primary endpoint in the int...

Mar 06, 2023

Acute ischemic stroke, contributing up to 80% of all stroke cases, is among the leading causes of death and morbidity, leaving around 50% of stroke survivors disabled worldwide. It is caused due to the blockage of an artery resulting in reduced blood flow to the brain that damages and interrupts brain functions. Hi...

Mar 03, 2023

There is a wider opportunity for BESREMi; Jakafi is not a direct competitor to Besremi, and there is uncertainty around Rusfertide’s uptake. BESREMi is expanding its horizon in the first-line treatment of Polycythemia vera; JAKAFI’s impressive growth in second-line treatment The polycythemia vera treatment par...

Mar 02, 2023

AI-powered Sensora Platform Launched by Eko for Cardiac Disease Detection On February 23, 2023, Eko, a digital healthcare company employing artificial intelligence (AI) against heart and lung disease, announced the launch of its SENSORA™ Cardiac Disease Detection Platform. The stethoscope, one of the m...